STRATAGRAFT is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).
STRATAGRAFT is for topical application to a prepared wound bed (excision/debridement). A STRATAGRAFT construct is an approximately 100 cm 2 (approximately 8 cm by 12.5 cm) off-white rectangle. A STRATAGRAFT construct may be trimmed to fit the shape and size of the wound area. The surface area of STRATAGRAFT to be applied should be equal to the surface area of the wound to be treated. Multiple constructs may be app...
STRATAGRAFT is an approximately 100 cm 2 rectangular sheet (approximately 8 cm by 12.5 cm) – (NDC 73612-200-01), loosely adherent to a polycarbonate membrane within a polystyrene frame and packaged in a sealed foil pouch contained within a carton. STRATAGRAFT is shipped on dry ice. The Hold Solution and Hold Dish are packaged separately and shipped at ambient temperature. Store STRATAGRAFT between -70°C and -90°C ...
www.mallinckrodt.com/stratatech
www.fda.gov/medwatchSTRATAGRAFT is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).
STRATAGRAFT is for topical application to a prepared wound bed (excision/debridement).
A STRATAGRAFT construct is an approximately 100 cm2 (approximately 8 cm by 12.5 cm) off-white rectangle. A STRATAGRAFT construct may be trimmed to fit the shape and size of the wound area. The surface area of STRATAGRAFT to be applied should be equal to the surface area of the wound to be treated.
Multiple constructs may be applied to cover large wound areas. If multiple constructs are required to cover the wound area, abut the STRATAGRAFT constructs, and it is not necessary to overlap the edges.
Each construct is for application to a single patient only.
STRATAGRAFT is to be prepared in an appropriate surgical environment.
STRATAGRAFT is supplied as follows:
The STRATAGRAFT carton contains a laminated foil pouch (Figure 1).
Figure 1: STRATAGRAFT carton and foil pouch
Within the pouch is the STRATAGRAFT Product Dish that contains STRATAGRAFT on a polystyrene insert tray (Figure 2).
Figure 2: STRATAGRAFT Product Dish containing the STRATAGRAFT construct
Inside the STRATAGRAFT Product Dish is the polystyrene insert tray that contains the STRATAGRAFT construct (Figure 3).
STRATAGRAFT is loosely adhered to a polycarbonate membrane contained within a polystyrene insert tray frame.
Figure 3: STRATAGRAFT Product Dish and Insert Tray containing STRATAGRAFT
Hold Solution is provided in a plastic bottle contained within a laminated, foil pouch [see Description (11)] (Figure 4).
Figure 4: Hold Solution within a laminated foil pouch
The Hold Dish is contained in a clear pouch (Figure 5) and consists of identical top and bottom portions (Figure 6).
Figure 5: Hold Dish contained within a clear pouch
Figure 6: Hold Dish handled in sterile field
Supplies:
The following supplies are not included but are needed for the preparation:
Preparation Instructions:
Following wound bed preparation (excision/debridement), determine the number of STRATAGRAFT constructs that need to be thawed.
The following instructions are for preparing one STRATAGRAFT construct. Two operators (one sterile operator and one non-sterile operator) are required.
If two or more STRATAGRAFT constructs are required, prepare them in one or more batches. STRATAGRAFT construct preparation should take approximately 20 minutes for a single construct or group of constructs.
Figure 7: Sterile operator (gray gloves) removes the sterile Hold Dish presented by the nonsterile operator (white gloves)
Figure 8: Sterile operator places the Hold Dish in the sterile field (gray rectangle)
Note: Steps 4-11 must be completed within 10 minutes of removal of STRATAGRAFT from the freezer or dry ice.
Figure 9: Remove foil pouch
Figure 10: Remove closed STRATAGRAFT Product Dish from foil pouch
Figure 11: Placement of STRATAGRAFT Product Dish in a nonsterile area
Figure 12: Nonsterile operator aseptically pours Hold Solution into the Hold Dish
Figure 13: Nonsterile operator (white gloves) opens the STRATAGRAFT Product Dish
Figure 14: Sterile operator (gray gloves) removes the STRATAGRAFT insert tray
Figure 15: Sterile operator places Insert Tray into the Hold Dish
Figure 16: Meshing STRATAGRAFT
STRATAGRAFT is applied in appropriate aseptic conditions by a trained healthcare provider.
Follow the steps below for topical application of STRATAGRAFT:
STRATAGRAFT is an off-white, rectangular sheet of approximately 100 cm2 (approximately 8 cm by 12.5 cm) consisting of a viable, bioengineered, allogeneic cellularized scaffold product derived from keratinocytes grown on gelled collagen containing dermal fibroblasts.
Do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin [See Description (11)].
STRATAGRAFT contains glycerin. Avoid glycerin in patients with known sensitivity (irritant reaction) to glycerin.
Severe hypersensitivity reactions may occur [see Contraindications (4)]. Monitor for both early and late symptoms and signs of hypersensitivity reaction following STRATAGRAFT application, and treat according to standard medical practice.
STRATAGRAFT contains cells from human donors and may transmit infectious diseases or infectious agents, e.g., viruses, bacteria, or other pathogens, including the agent that causes transmissible spongiform encephalopathy (TSE, also known as Creutzfeldt-Jakob disease (CJD) or variant CJD).
STRATAGRAFT is a xenotransplantation product because of a historic exposure of the keratinocyte cells to well-characterized mouse cells. The cell banks have been tested and found to be free of detectable adventitious agents and mouse cells are no longer used in the manufacture of STRATAGRAFT [see Description (11)].
STRATAGRAFT was established to be free of detectable pathogens using FDA-recommended characterization procedures and tests including molecular and analytical testing.
Transmission of infectious diseases or agents by STRATAGRAFT has not been reported.
Recipients of xenotransplantation products such as STRATAGRAFT are generally not eligible to donate whole blood or blood components, including source plasma and source leukocytes. However, individual blood collection establishments may request an exception.
STRATAGRAFT recipients who otherwise meet donor requirements are eligible to donate human cells, tissues, or cellular or tissue-based products (HCT/Ps), human milk, ova, sperm, or organs for transplantation.
The most common adverse reactions (incidence ≥2%) were itching (pruritus), blisters, hypertrophic scar and impaired healing. (Table 1).
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflect exposure to STRATAGRAFT in four randomized, within-subject-controlled studies conducted in the United States, including two clinical studies in patients with deep partial-thickness thermal burns (Study 1 and Study 2) and two clinical studies in patients with full-thickness complex skin defects due to thermal burns or other causes. A total of 119 adult patients (101 patients with deep partial-thickness thermal burn, and 18 patients with full-thickness complex skin defects) received topical application of STRATAGRAFT. The patient population ranged in age from 19 to 79 years (mean age 43 years). Each patient received topical application of STRATAGRAFT at one wound site and either autografting (104 patients) or cadaver allografts (15 patients) as intrapatient comparators at another wound site. The most frequent adverse reactions (incidence ≥2%) observed in the 4 studies are summarized in Table 1. No patients discontinued study participation due to adverse reactions.
| Adverse Reaction | Patients n (%)* |
|---|---|
| Pruritus (Itching) | 13 (11) |
| Blisters | 5 (4) |
| Hypertrophic Scar | 3 (3) |
| Impaired Healing | 3 (3) |
* If a patient had more than one incidence of an adverse reaction, the patient was counted only once.
Overall, the safety profile of STRATAGRAFT with regard to wound-related events, including erythema, swelling, local warmth and wound site infections, was similar to that of autografting in these studies.
There were no reports of rejection of STRATAGRAFT in the clinical studies.
The safety of STRATAGRAFT beyond 12 months was not evaluated in the clinical studies.
The use of mafenide acetate is not recommended following application of STRATAGRAFT. This topical antimicrobial has been shown to reduce keratinocyte viability and disrupt the integrity of tissue-engineered human skin substitutes composed of NIKS® keratinocytes or primary keratinocytes.1
The use of silver-containing antimicrobials or dressings is not recommended because in vitro data suggest silver may decrease the viability of keratinocytes and human dermal fibroblasts.2
The use of antimicrobial chlorhexidine solution on the wound following application of STRATAGRAFT is not recommended. This material has been shown to be toxic to keratinocytes and human dermal fibroblasts.3
Risk Summary
There are no available data regarding STRATAGRAFT use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with STRATAGRAFT to assess whether it can cause fetal harm when administered to a pregnant woman.
In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Risk Summary
There is no information available on the presence of STRATAGRAFT in human milk, the effect on the breastfed infant, or the effect on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for STRATAGRAFT and any potential adverse effects on the breast-fed infant from STRATAGRAFT or from the underlying maternal condition.
The safety and effectiveness of STRATAGRAFT in pediatric patients (< 18 years) have not been established.
Eight patients aged 65 years and older were enrolled in Study 1. Although no differences in safety or efficacy were observed between patients aged 65 years and older and younger patients, the number of patients aged 65 years and older was not sufficient to determine whether they responded differently from younger patients.
STRATAGRAFT is a viable, bioengineered, allogeneic, cellularized scaffold product that contains a fully-stratified epithelial layer comprised of differentiated, multilayered, epidermal keratinocytes from a single human donor. The keratinocytes are grown on a purified murine Type I collagen matrix embedded with fibroblasts from a second human donor.
STRATAGRAFT is produced from well-characterized human keratinocyte and fibroblast cell banks that contain no detectable pathogens. The cells are metabolically active allogeneic NIKS keratinocytes and dermal fibroblasts.
STRATAGRAFT is a xenotransplantation product because the keratinocyte component was originally derived in the presence of a mouse cell line. However, mouse cells are no longer used to manufacture STRATAGRAFT. No mouse cells or mouse-derived infectious agents are detectable in STRATAGRAFT.
STRATAGRAFT product manufacture includes reagents derived from animal materials, including murine collagen, calf serum, porcine trypsin and purified bovine serum albumin.
STRATAGRAFT construct is loosely adherent to a supportive polycarbonate membrane insert and treated in glycerin-containing media. Each cryopreserved STRATAGRAFT construct is supplied with Hold Solution and Hold Dish, which are used for preparing STRATAGRAFT [see How Supplied/Storage and Handling (16)].
The Hold Solution is a cell-culture medium that is not supplemented with growth factors.
STRATAGRAFT is an allogeneic cellularized scaffold product containing metabolically active cells that produce and secrete a variety of growth factors and cytokines. In vitro studies have shown that STRATAGRAFT secretes human growth factors and cytokines, and contains human extracellular matrix proteins. Growth factors, cytokines, and extracellular matrix proteins are known to be involved in wound repair and regeneration.
STRATAGRAFT does not remain permanently engrafted, but is replaced by the patient's own cells over time, eliminating or reducing the need for autografting to attain definitive closure of the majority of treated wounds. A total of 85 patients in Study 1 and Study 2 were evaluated at 3 months for persistence of allogeneic STRATAGRAFT DNA at the treatment site. STRATAGRAFT-associated DNA was not detected in these patients.
The pharmacodynamic effects of STRATAGRAFT are not known.
The pharmacokinetic effects of STRATAGRAFT are not known.
No animal studies were conducted to evaluate the effects of STRATAGRAFT on carcinogenesis, mutagenesis, or impairment of fertility. Evaluation of tumorigenic potential consisted of the following studies:
Karyotype Stability
The NIKS keratinocytes and human dermal fibroblasts contained in STRATAGRAFT are karyotypically stable.
In Vitro Studies
The NIKS keratinocytes and human dermal fibroblasts cultured for 43 and 6 passages, respectively, did not exhibit anchorage-independent growth (a standard assay that evaluates the potential for cellular transformation). STRATAGRAFT contains NIKS keratinocytes and human dermal fibroblasts that are at passage 40 and 7, respectively.
In Vivo Studies
A single subcutaneous injection of NIKS keratinocytes into immunodeficient mice did not result in tumor formation by 23 weeks post-injection. Topical application of STRATAGRAFT on full-thickness excisional wounds in immunodeficient mice did not result in tumor formation by 20 weeks post-dose.
Toxicity
No evidence of local or systemic toxicity was observed in immunocompromised athymic nude mice exposed to STRATAGRAFT. Administration of 14 cm2 (approximately 25% Total Body Surface Area) of STRATAGRAFT was applied to full-thickness excisional wounds, followed by assessment for local or systemic toxicity from 90 to 140 days (13 to 20 weeks).
The efficacy of STRATAGRAFT in adult patients with thermal burns containing intact dermal elements for which surgical excision and autografting were clinically indicated was evaluated in two randomized, open-label, intrapatient-controlled, multicenter clinical studies of 12 months duration (Study 1 and Study 2). In both studies, two comparable wound sites of each patient were selected and randomized to receive either topical application of STRATAGRAFT or autograft. Autografts served as the intrapatient control.
Study 1 enrolled 71 adult patients with acute thermal burns containing intact dermal elements (deep partial-thickness burns) involving 3 to 37% total body surface area (TBSA). The time from burn to study treatment was 1 to 18 days. The size of the STRATAGRAFT-treated wound was 12 to 960 cm2. The mean age was 44 years (19 to 79 years) with 78% male. Seventy-eight percent of patients were White, 20% were Black or African-American, and the remainder were Asian or Other. Efficacy was established on the basis of: (1) the difference in the percent area of the STRATAGRAFT treatment site and the control autograft treatment site that required autografting by 3 months following treatment, and (2) the proportion of patients achieving durable wound closure of the STRATAGRAFT treatment site at 3 months without autograft placement. Durable wound closure at 3 months was defined as wound closure at two consecutive study visits at least 2 weeks, but no more than 5 months apart, and including or encompassing the 3-month time point.
The difference in the percent area of STRATAGRAFT and control autograft treatment sites that required autografting by 3 months was 98%±17% (p<0.0001). Three patients had part or all of their STRATAGRAFT treatment site autografted by 3 months, and two of the three patients also had part or all of their autograft control study site re-grafted. Donor site harvest was eliminated for 96% (68/71) of STRATAGRAFT-treated burn sites. As a result, pain and scarring were significantly reduced at these potential donor sites that were spared and remained intact (p<0.0001). The cosmesis was similar between STRATAGRAFT-treated sites and autograft-treated sites.
The proportion of patients achieving durable closure of the STRATAGRAFT treatment site at 3 months without autograft placement was 83% (95% CI: 74, 92). The proportion of patients achieving durable closure of the autograft control treatment site at 3 months without additional autograft placement was 86% (95% CI: 78, 94).
In subgroups of race, ethnicity, sex, age, burn size in percentage of TBSA, STRATAGRAFT treatment area, and Baux scores (a scoring system to estimate mortality due to burn), efficacy results were in general consistent with the results in the overall Study 1 population.
Study 2 enrolled 30 adult patients with acute thermal burns containing intact dermal elements (deep partial-thickness burn) and involving 3 to 49% TBSA. The time from burn to study treatment ranged from 3 to 13 days. The size of the STRATAGRAFT-treated wound was 52 to 440 cm2. The mean age was 41 years (21 – 63 years). Ninety-three percent of patients were White and 7% were Black or African-American. Men accounted for 70% of the population.
Efficacy was evaluated on the basis of: (1) the percent area of STRATAGRAFT treatment site autografted by 28 days after STRATAGRAFT treatment, and (2) the proportion of treatment sites that achieved complete wound closure by 3 months. Complete wound closure was defined as ≥95% re-epithelialization in the absence of drainage.
No STRATAGRAFT treatment site required autografts by 28 days. Between 28 days and 3 months, one patient had both the STRATAGRAFT treatment site and the autograft site treated subsequently with autograft, and a second patient had 25% of the STRATAGRAFT treatment site autografted. At 3 months, 93.1% of STRATAGRAFT treatment sites and 100% of autograft treatment sites achieved complete wound closure. All STRATAGRAFT treatment sites that achieved complete wound closure at 3 months remained closed when evaluated at 6 months and 12 months after treatment.
STRATAGRAFT is an approximately 100 cm2 rectangular sheet (approximately 8 cm by 12.5 cm) – (NDC 73612-200-01), loosely adherent to a polycarbonate membrane within a polystyrene frame and packaged in a sealed foil pouch contained within a carton.
STRATAGRAFT is shipped on dry ice. The Hold Solution and Hold Dish are packaged separately and shipped at ambient temperature.
Store STRATAGRAFT between -70°C and -90°C (-94°F to -130°F).
Store the Hold Solution between 2°C and 8°C (36°F and 46°F).
Store Hold Dishes at ambient temperature.
Do not use any of the above components if they have been compromised.
Dispose of unused STRATAGRAFT as surgical biohazardous waste in accordance with local requirements.
Dispose of materials that have come into contact with STRATAGRAFT as surgical biohazardous waste in accordance with local requirements.
Contact Customer Care at 1-877-647-2239 for further instructions.
Advise patients to read the FDA-approved patient labeling (Patient Information).
Advise patients of the following risks:
Xenotransplantation nature of STRATAGRAFT
Inform patients that mouse cells were used in the early development of the NIKS keratinocyte master cell bank. Therefore, STRATAGRAFT is a xenotransplantation product, even though mouse cells are no longer used in the manufacture of STRATAGRAFT. Please see the attached patient instruction sheet for additional instruction.
After application of STRATAGRAFT, provide the following post-procedure instructions:
Manufactured and Distributed by:
Stratatech Corporation
510 Charmany Drive, Suite 150
Madison, WI 53719
Ph.: 1-877-647-2239
U.S. License #2144
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024 Mallinckrodt.
Part number SPC-RM-0159 Rev.3
allogeneic cultured keratinocytes and dermal fibroblasts
in murine collagen-dsat
STRATAGRAFT®
Patient Information
This guide is to help you understand STRATAGRAFT and its use for the treatment of burns. This guide does not take the place of talking with your healthcare provider about STRATAGRAFT. If you have questions about STRATAGRAFT, talk to your healthcare provider.
STRATAGRAFT is a biologic drug approved by the Food and Drug Administration (FDA) for use in adult patients who have a specific type of burn. STRATAGRAFT is placed onto your burn by your healthcare provider. Over time, your skin cells should grow to replace the skin cells lost to the burn.
STRATAGRAFT is available by prescription only.
U.S. License Number: 2144
Manufactured by:
Stratatech Corporation
510 Charmany Drive, Suite 150
Madison, WI 53719
Phone: 1-877-647-2239
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024 Mallinckrodt.
Glossary/Definitions of Terms
Autograft: a piece of your own skin tissue used to replace skin lost to burn.
Bilayer construct: product containing two different layers of skin cells in a format similar to human skin.
Biologic drug: a drug product that is produced from living organisms or contains components of living organisms.
Bovine: relating to cattle.
Dermal fibroblasts: a type of cell from the inner layer of skin that helps the skin to recover from injury.
ex-vivo: outside of the living body.
Hypersensitivity: condition in which there is an exaggerated response by the body to something foreign.
Infectious agent: organisms that might cause an infection or infectious disease; includes bacteria, fungi, viruses, and parasites.
Keratinocytes: cells that make up the outer surface of the skin that helps the skin to recover from injury.
Murine: relating to rodents.
Porcine: relating to pigs.
Skin grafts: a piece of tissue used for replacing skin lost to burn.
Xenotransplantation product: product that contains live cells, tissues, or organs from a non-human animal source or human body fluids, cells, tissues, or organs that have come into ex-vivo contact with live non-human animal cells, tissues, or organs.
What is STRATAGRAFT?
STRATAGRAFT construct is produced from two kinds of human skin cells (keratinocytes and dermal fibroblasts). To produce STRATAGRAFT, the cells are allowed to grow together to make a bilayered construct that is similar to skin.
STRATAGRAFT is a xenotransplantation product because in the past, one of the cell types used to make STRATAGRAFT was grown with mouse cells. The cell banks have been tested and found to be free of detectable infectious agents and mouse cells are no longer used in the manufacture of STRATAGRAFT.
There have been no identified health concerns associated with these mouse cells.
No infectious agents have been detected in STRATAGRAFT.
Who should use STRATAGRAFT?
Adults may need STRATAGRAFT if they have a deep burn(s). Your doctor will evaluate if STRATAGRAFT may be right to treat your burn(s).
Why may STRATAGRAFT help your condition?
For many deep burns, one treatment type is the removal of the damaged, burned skin, and replacement with a skin graft. These skin grafts may be taken from your own healthy skin on your body and moved to the burned area to help it heal. When skin grafts are taken from your body, it is called an autograft. This procedure leaves a new wound where the healthy skin was taken.
If your doctor recommends that your burn wound be treated with STRATAGRAFT, then your healthcare provider will place STRATAGRAFT on your burn instead of using a piece of your own healthy skin. In most cases, treatment with STRATAGRAFT avoids or greatly decreases the amount of healthy skin that is taken for grafting.
STRATAGRAFT will likely allow your own skin cells to grow and heal the burned area over time.
When should STRATAGRAFT not be used?
You should not be treated with STRATAGRAFT if you have an allergy to STRATAGRAFT or any of the components of STRATAGRAFT, including murine collagen or bovine or porcine products.
What are the risks associated with STRATAGRAFT?
The safety of STRATAGRAFT was similar to that of autografting in clinical studies.
To report SUSPECTED ADVERSE REACTIONS, contact Customer Care at 1-877-647-2239 or www.mallinckrodt.com/stratatech or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Recipients of xenotransplantation products are generally not eligible to donate whole blood, blood components, source plasma or source leukocytes. However, individual blood banks may request an exception, so if you wish to donate blood or blood products check with your donation center.
STRATAGRAFT recipients who otherwise meet the donor requirements are eligible to donate human cells, tissues, breast milk, ova, sperm, or body parts for transplantation.
What are the potential complications of burns and skin grafting?
Severe burns may cause many complications to both the skin and other parts of the body. These complications can be very serious and life-threatening.
In the clinical studies, complications seen after treatment with STRATAGRAFT were typical of severe burns. Patients experienced itching, blisters, scarring, and impaired healing at the treatment site.
To help avoid complications after surgery, follow these instructions:
SPC-LBL-0982 Rev.3
01/2024
NDC 73612-200-01
Rx Only
allogeneic cultured keratinocytes and dermal
fibroblasts in murine collagen-dsat
STRATAGRAFT®
For Single-Use Only
For Topical Application Only
Contains 1 Construct
NDC 73612-201-01
Rx Only
allogeneic cultured keratinocytes and dermal
fibroblasts in murine collagen - dsat
STRATAGRAFT®
Sample - Not for Resale
For Single-Use Only
For Topical Application Only
Contains 1 Construct
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 73612-200-01 | EA - Each | 73612-200 | f06525d5-c538-4c71-ac2b-8d89567e0b3b | 1 | 2021-11-09 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 73612-200 | 73612-200-01 |
| 73612-201 | 73612-201-01 |
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125730 | StrataGraft | Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat | 351(a) | Disc | 2026-09-01 |
Every source-derived ingredient row is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d0890ef4-afbb-4f18-9c21-e81492e4edf7 | f9aa1103-ff31-4a93-b319-1ccb604f0b0d | 2024-12-04 | Warnings, Adverse reactions | f9aa1103-ff31-4a93-b319-1ccb604f0b0d |
Adverse event summaries are temporarily unavailable. Other product information remains available.